September 19th 2023
The AZALEA-TIMI 71 trial was stopped early due to an "overwhelming reduction" in a composite endpoint of major bleeding events compared to rivaroxaban standard of care.
September 12th 2023
Your daily dose of clinical news you may have missed.
September 1st 2023
Atrial fibrillation prevalence is rising across socioeconomic strata globally, the new analysis finds, with effects of BMI, ETOH, and sedentary behavior shifting as key drivers.
August 29th 2023
The first 10 drugs identified for negotiations under the Inflation Reduction Act include several well advertised agents indicated to treat diabetes, heart failure, and other chronic diseases.
August 28th 2023
Oldest and most frail elderly were at more than 60% greater risk of bleeding when switched from a VKA than those who remained on the traditional agent.
Expert Details the Top 3 CV Complications Seen in Patients with Obesity
Internist and obesity medicine specialist Alina Elperin, MD, details the most common cardiovascular complications that she has observed in patients with obesity.
Concentrated and Distributed Physical Activity Similarly Lower Risk for CV Events
Regardless of the pattern of physical activity, it may reduce risk across a spectrum of cardiovascular diseases, say study authors. So, just do it!
Less than Half of Patients with New AF Diagnosis Prescribed Oral Anticoagulation within 6 Months
Factors positively associated with a timely first OAC Rx among the 41.3% who received one included male sex, certain comorbidities, other current medications, and obesity.
Milvexian, FXIa Inhibitor, Wins US FDA Fast Track Designation for 3 Indications in Phase 3 Trial Program
Proposed indications for the investigational factor XIa inhibitor are: stroke prevention after acute ischemic stroke or high-risk transient ischemic attack; recent acute coronary syndrome; and atrial fibrillation.
Asundexian Granted FDA Fast Track Designation for Stroke Prevention in Patients with AF
Bayer's investigational FXIa inhibitor is currently being studied in a large-scale phase 3 development program expected to enroll more than 27 000 participants.
Statin Therapy May be Protective Against Stroke in People with Atrial Fibrillation: New Study
Statin therapy initiated within 1 year of diagnosis of atrial fibrillation reduced the risk of ischemic stroke or systemic embolism by nearly 20%.
Daily Dose: Physician and Patient Perspectives on Oral Anticoagulation for AF
"Disconnect" on Oral Anticoagulation Observed Between Patients with AF and their Physicians
More than two-thirds of patients not receiving OAC were open to beginning treatment but many of their physicians were not, according to a study of PINNACLE Registry participants.
Daily Dose: Statin Effects in AF-related Stroke
New Data Support Use of Statins in Patients with New-onset Atrial Fibrillation to Prevent Stroke, Transient Ischemic Attack
EHRA 2023: Patients with AF who started statins within a year of diagnosis had reduced risks of stroke and TIA compared with those who did not start statins.
Daily Dose: Apple Watch for Detection of Atrial Fibrillation
New Data Suggest Apple Watch Algorithm is Accurate in Atrial Fibrillation Detection
An Apple Watch feature designed to detect atrial fibrillation was associated with a low rate of false-positive detections and high specificity in persons with AF.
Benefits of Early Rhythm Control Similar in Women and Men with Atrial Fibrillation, According to New Research
Among patients with recently detected AF, early rhythm control improved cardiovascular outcomes in patients of either sex without differences in safety.
Daily Dose: Autoimmune Disorders Associated with New-onset Atrial Fibrillation
Autoimmune Disorders Associated with New-onset AF and More Distinct in Women, Shows New Study
Findings elaborate on the pathophysiological differences in autoimmunity and atrial fibrillation risk between men and women.
Cardiovascular Disease: Top Papers in 2022
Find a compact sampling of 2022 cardiovascular disease research reviewed on Patient Care, chosen by the editorial staff.
As Many as 1 in 3 High-risk Patients with Atrial Fibrillation are Not Prescribed Anticoagulation
The low rate of stroke prevention with oral anticoagulation in patients with atrial fibrillation is cause for significant concern, say investigators.
Apixaban May be the Safer DOAC in Afib, Suggests First Large Comparative Analysis
Apixaban was associated with up to a 28% lower risk of GI bleeding vs the 3 other direct oral anticoagulants in the first large-scale comparative analysis.
Black Patients with Afib Significantly Less Likely to Receive Oral Anticoagulation at Hospital Discharge
Black patients were also at significantly increased risk of stroke, bleeding, and mortality vs White patients 1 year following discharge.
The Daily Dose: Dueling DOACS
Your daily dose of the clinical news you may have missed.
Apixaban Found More Effective than Rivaroxaban in Patients with AFib and Valvular Heart Disease
In the absence of randomized controlled head-to-head trials comparing the 2 anticoagulants, study authors say clinicians should consider their findings when choosing treatment.
Migraine with Aura Characterized as Independent Risk Factor for Atrial Fibrillation
Adults with migraine with aura were found at significantly greater risk for AF and those younger than age 55 years were particularly vulnerable, write Mayo Clinic investigators.
Hypertension-related CVD Most Common ED Presentation in the US
Approximately one-third of CV-related ED visits are for hypertension-related conditions, including 13% for essential hypertension among women.
Intervention Reduces Aspirin Use in Patients with AF, VTE Taking Warfarin, Improves Outcomes
An aspirin deprescribing intervention at anticoagulation clinics led to a 50% reduction in use among patients with AF, VTE prescribed warfarin.
Abelacimab Receives Fast Track Designation from FDA for Prevention of Stroke, Systemic Embolism in Patients with Atrial Fibrillation
Abelacimab is a dual-acting, fully human monoclonal antibody that selectively targets both factor XI and factor XIa with high affinity.
Wrist-worn Devices Prove Cost-effective for AF Screening of 30 Million in Economic Simulation
Screening for atrial fibrillation with 6 wrist-worn wearable devices proved more cost effective than no screening and had greater relative benefit than using traditional modalities.
Risks for Diabetes and CVD Spike in Early COVID-19 Infection, May Diminish Over 12 Months
Type 1 diabetes diagnoses increased by 81% during the 4-week acute phase of COVID-19 in UK patients and CVD diagnoses rose 6-fold, according to a large population-based study.
Early Rhythm Control May Not be as Effective in Adults with Newly Diagnosed Atrial Fibrillation
Early rhythm control reduced CV complications regardless of AF pattern but for patients with a first AF diagnosis, risks for hospitalization and ACS were higher after early rhythm therapy.
Smartwatch Detection of Afib: KardiaBand Outperforms Apple Watch Series 4
Called SMART WARS, a new study assessed diagnostic utility of the 2 wearable devices in older adults and considered combined device/clinician interpretation of ECG readings.
Stroke Patients Very Likely to Present with Undiagnosed Risk Factors
Three-quarters of stroke patients in a Swiss registry had at least 1 undiagnosed risk factor at the time of the event, most commonly hyperlipidemia or hypertension.
2 Clarke Drive Cranbury, NJ 08512